Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lifestance Health (LFST)

LifeStance Q4 revenue up 16% to $325.5 million; net loss narrows to $7.1 million

Positive Impact 3 of 5 earnings Written later

LifeStance Health Group reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue grew 19% for the full year to $1.25 billion, and the full-year net loss narrowed to $57.4 million from $186.3 million in 2023. The company also expects 2025 revenue of $1.40 billion to $1.44 billion and Adjusted EBITDA of $130 million to $150 million.

Key points

  • Q4 2024 revenue was $325.5 million, up 16%; full-year revenue was $1.25 billion, up 19%.
  • Q4 2024 net loss was $7.1 million versus $45.0 million a year earlier; full-year net loss was $57.4 million versus $186.3 million.
  • Full-year 2024 Adjusted EBITDA was $119.7 million, up 103%; Free Cash Flow was $85.7 million.
  • 2025 guidance: revenue of $1.40 billion to $1.44 billion, Center Margin of $440 million to $464 million, Adjusted EBITDA of $130 million to $150 million; Q1 2025 revenue of $320 million to $340 million.

The filing

CompanyLifestance Health (LFST)
Form8-K, current report
Filed with the SECFeb 26, 2025, 6:51 PM ET
Accession number0000950170-25-028099

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.